Trial · NCT01369212
Trial comparisons17
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
1 to 17 of 17
Download this page as JSON| Comparison | Source |
|---|---|
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With Normal Alanine Transaminase (ALT) Levels at Week 240 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With Alanine Transaminase(ALT) Levels <= 38 U/L for Males and <=25 for Females at Week 192 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With HBeAg Seroconversion at Week 192 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With HBsAg Seroconversion at Week 192 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With Normal Alanine Transaminase (ALT) Levels at Week 192 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With HBeAg Seroconversion at Week 240 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With Serious Adverse Events | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With HBV DNA<1000 IU/mL at Week 240 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With HBV DNA<1000 IU/mL at Week 192 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With Hepatitis B e Antigen (HBeAg) Loss at Week 192 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With HBV DNA<20 IU/mL at Week 192 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With Adverse Events | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With HBsAg Seroconversion at Week 240 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: deaths from any cause | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With HBeAg Loss at Week 240 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: Number of Participants With HBV DNA<20 IU/mL at Week 240 | Trial comparisons |
| Tenofovir vs Peginterferon-alfa 2a and Tenofovir: serious adverse events | Trial comparisons |
trials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01369212/comparisons